TMDX's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.21 -- higher than just 4.51% of US-listed equities with positive expected earnings growth.
TMDX's went public 1.5 years ago, making it older than merely 1.94% of listed US stocks we're tracking.
With a price/sales ratio of 14.2, TransMedics Group Inc has a higher such ratio than 89.77% of stocks in our set.
If you're looking for stocks that are quantitatively similar to TransMedics Group Inc, a group of peers worth examining would be NWBO, MOSY, ASTC, KMDA, and UTSI.
TMDX's SEC filings can be seen here. And to visit TransMedics Group Inc's official web site, go to www.transmedics.com.
TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.
TransMedics (TMDX) has announced that the FDA has temporarily postponed the Advisory Committee (AdCom) meeting to review its premarket approval application for its OCS Heart, which was originally scheduled for October 7, to have more time to review additional and longer-term data from the OCS Heart EXPAND trial and EXPAND Continued...
ANDOVER, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter after market close on Wednesday, August 5, 2020. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (866) 221-1172 for domestic callers or (270) 215-9603 for international callers, followed by Conference ID: 9858896. A live and archived webcast of the event will be available on the “Investors” section of the TransMedics website at ht...
Transplant patients have advanced disease states that are best addressed by replacing the ailing organ with a healthy one from a donor. Otherwise, administering care to such critically ill patients carries extremely high cost despite having limited benefits to longevity or quality of life. Unfortunately, almost five patients die each...
Shares of TransMedics Group (NASDAQ: TMDX), a medical device company focused on organ transportation, fell about 16% as of 10:37 a.m. EDT on Wednesday after the company announced the pricing details of a common stock offering. TransMedics let investors know on Tuesday that it wanted to raise about $60 million through a secondary common-stock offering. TransMedics is selling 5 million shares for $14 each.